- Home
- A-Z Publications
- CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders)
- Previous Issues
- Volume 9, Issue 3, 2010
CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders) - Volume 9, Issue 3, 2010
Volume 9, Issue 3, 2010
-
-
Commentary (Research Highlights)
More LessAlzheimer's disease (AD) is a debilitating neurodegenerative disorder characterized pathologically by the presence of extracellular senile plaques and intracellular neurofibrillary tangles. The main protein components of senile plaques are amyloid-β peptides (Aβ), secreted proteolytic derivatives of the amyloid precursor protein (APP). Excessive synaptic loss is thought to be one of the earliest events in AD, and synaptic Read More
-
-
-
Editorial [Hot topic: Neuroprotection in ALS: From Pathology to Treatment (Guest Editors: Gabriele Siciliano and Luigi Murri)]
By Luigi MurriThese past years have seen the publication of numerous scientific articles and books on amyotrophic lateral sclerosis (ALS) that probably reflect the great human and social impact of this devastating disease on affected patients and relatives. It is common to define ALS as a “treatable”, although “far from being curable”, disorder. Multidisciplinary teams in specialized ALS centers are looking to identify reliable pathogenic Read More
-
-
-
Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics?
More LessAmyotrophic lateral sclerosis (ALS) is a difficult disease to study as it is mostly sporadic and rapidly progressive. Identification of genes causing familial ALS (FALS) has been instrumental in advancing our understanding of ALS pathogenesis, most notably with the use of mutant superoxide dismutase 1 (SOD1) models of disease. For 15 years SOD1 models have been the backbone of ALS research, but no effective treatment Read More
-
-
-
The Role of Autophagy: What can be Learned from the Genetic Forms of Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder caused by loss of motor neurons both in the brain and spinal cord, which dramatically reduces life expectancy. ALS occurs either in familial ALS or, more frequently, in sporadic ALS forms. Several mechanisms have been postulated to underlie motor neuron death. In the present paper, starting from some of the genes related to familial ALS, we overview a Read More
-
-
-
Histone Deacetylation and Motor Neuron Degeneration
Authors: S. Schmalbach and S. PetriAmyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with progressive muscular wasting and paralysis due to loss of motor neurons in the primary motor cortex, brainstem and spinal cord. Alterations of transcriptional activity due to an unbalance of the activity of histone acetyl transferases (HAT) and histone deacetylases (HDACs) have been described in a variety of neurodegenerative conditions in Read More
-
-
-
Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
Authors: N. Ticozzi, A. Ratti and V. SilaniThe presence of protein inclusions within the central nervous system is a characteristic of most neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Aggregates may induce cell death trough several mechanisms, such as sequestration of essential cellular components, clogging of the proteasome system, and/or disruption of axonal transport. The neuropathological signature of ALS is represented by the Read More
-
-
-
Amyotrophic Lateral Sclerosis and Excitotoxicity: From Pathological Mechanism to Therapeutic Target
Authors: E. Bogaert, C. d'Ydewalle and L. Van Den BoschGlutamate-induced excitotoxicity is responsible for neuronal death in acute neurological conditions as well as in chronic neurodegeneration. In this review, we give an overview of the contribution of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis (ALS). The selective motor neuron death that is the hallmark of this neurodegenerative disease seems to be related to a number of intrinsic characteristics of thes Read More
-
-
-
Clinical Trials for Neuroprotection in ALS
Authors: G. Siciliano, C. Carlesi, L. Pasquali, S. Piazza, S. Pietracupa, F. Fornai, S. Ruggieri and L. MurriOwing to uncertainty on the pathogenic mechanisms underlying motor neuron degeneration in amyotrophic lateral sclerosis (ALS) riluzole remains the only available therapy, with only marginal effects on disease survival. Here we review some of the recent advances in the search for disease-modifying drugs for ALS based on their putative neuroprotective effetcs. A number of more or less established agents have recently bee Read More
-
-
-
Stem Cells in Amyotrophic Lateral Sclerosis: Motor Neuron Protection or Replacement?
Authors: V. Silani, C. Calzarossa, L. Cova and N. TicozziGiven the lack of effective drug treatments for amyotrophic lateral sclerosis (ALS), compelling preclinical data on stem cell research has targeted this disease as a candidate for stem cell treatment. Stem cell transplantation has been effective in several animal models, but the underlying biological pathways of restorative processes are still unresolved. Several mechanisms such as cell fusion, neurotrophic factor release, e Read More
-
-
-
Involvement of Immune Response in the Pathogenesis of Amyotrophic Lateral Sclerosis: A Therapeutic Opportunity?
More LessThe immune system has been found to be involved with positive and negative effects in the nervous system of amyotrophic lateral sclerosis (ALS) patients. In general, T cells, B cells, NK cells, mast cells, macrophages, dendritic cells, microglia, antibodies, complement and cytokines participate in limiting damage. Several mechanisms of action, such as production of neurotrophic growth factors and interaction with neurons and Read More
-
-
-
Repetitive Transcranial Magnetic Stimulation for ALS
Authors: M. Dileone, P. Profice, F. Pilato, F. Ranieri, F. Capone, G. Musumeci, L. Florio, R. Di Iorio and V. Di LazzaroAmyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease affecting upper and lower motor neurons characterized by progressive weakness, respiratory failure and death within 3-5 years. It has been proposed that glutamate-related excitotoxicity may promote motor neuron death in ALS. Glutamatergic circuits of the human motor cortex can be activated noninvasively using transcranial magneti Read More
-
-
-
Recent Therapeutic Advances for Treating Medulloblastoma: Focus on New Molecular Targets
Authors: A.L. Schmidt, A.L. Brunetto, G. Schwartsmann, R. Roesler and A.L. AbujamraMedulloblastoma is the most common malignant brain tumor in children. This malignant tumor of the cerebellum commonly affects children and is believed to arise from the precursor cells of the external granule layer or neuroepithelial cells from the cerebellar ventricular zone of the developing cerebellum. The standard treatment, consisting of surgery, craniospinal radiotherapy and chemotherapy, still provides a poo Read More
-
-
-
Glia as a Turning Point in the Therapeutic Strategy of Parkinson's Disease
Parkinsons'disease (PD) is a common neurodegenerative disorder characterized by the presence of tremor, muscle rigidity, slowness of voluntary movements and postural instability. One of the pathological hallmarks of PD is loss of dopaminergic (DAergic) neurons in the subtantia nigra pars compacta (SNpc). The cause and mechanisms underlying the demise of nigrostriatal DAergic neurons are not fully understood, but inter Read More
-
-
-
Mechanisms of Oxidative Glutamate Toxicity: The Glutamate/Cystine Antiporter System xc¯ as a Neuroprotective Drug Target
Authors: Philipp Albrecht, Jan Lewerenz, Sonja Dittmer, Rebecca Noack, Pamela Maher and Axel MethnerThe glutamate/cystine antiporter system xc¯ transports cystine into cells in exchange for the important neurotransmitter glutamate at a ratio of 1:1. It is composed of a specific light chain, xCT, and a heavy chain, 4F2, linked by a disulfide bridge. Both subunits are localized prominently in the mouse and human brain especially in border areas between the brain and periphery including vascular endothelial cells, ependymal cell Read More
-
Volumes & issues
-
Volume 24 (2025)
-
Volume 23 (2024)
-
Volume 22 (2023)
-
Volume 21 (2022)
-
Volume 20 (2021)
-
Volume 19 (2020)
-
Volume 18 (2019)
-
Volume 17 (2018)
-
Volume 16 (2017)
-
Volume 15 (2016)
-
Volume 14 (2015)
-
Volume 13 (2014)
-
Volume 12 (2013)
-
Volume 11 (2012)
-
Volume 10 (2011)
-
Volume 9 (2010)
-
Volume 8 (2009)
-
Volume 7 (2008)
-
Volume 6 (2007)
-
Volume 5 (2006)
Most Read This Month
Article
content/journals/cnsnddt
Journal
10
5
false
en

Most Cited Most Cited RSS feed
-
-
A Retrospective, Multi-Center Cohort Study Evaluating the Severity- Related Effects of Cerebrolysin Treatment on Clinical Outcomes in Traumatic Brain Injury
Authors: Dafin F. Muresanu, Alexandru V. Ciurea, Radu M. Gorgan, Eva Gheorghita, Stefan I. Florian, Horatiu Stan, Alin Blaga, Nicolai Ianovici, Stefan M. Iencean, Dana Turliuc, Horia B. Davidescu, Cornel Mihalache, Felix M. Brehar, Anca . S. Mihaescu, Dinu C. Mardare, Aurelian Anghelescu, Carmen Chiparus, Magdalena Lapadat, Viorel Pruna, Dumitru Mohan, Constantin Costea, Daniel Costea, Claudiu Palade, Narcisa Bucur, Jesus Figueroa and Anton Alvarez
-
-
-
- More Less